Platelets and Their Role in Hemostasis

Introduction

• Platelets are small yet highly specialized cell fragments essential for hemostasis. They rapidly form a primary plug, support clot formation, and prevent blood loss. Their structure enables adhesion, activation, and aggregation, while reduced counts or increased destruction can lead to significant bleeding complications.

Definition And Concept

• Hemostasis is the physiological process that stops bleeding while maintaining blood in a fluid state within vessels. It involves coordinated interaction of the vessel wall, platelets, and plasma proteins.
• Hemostasis occurs in two major stages: primary and secondary phases.

Primary hemostasis:

• It is the initial response to vascular injury.
• Platelets adhere to damaged endothelium and form a temporary platelet plug. This stage limits blood loss but does not provide long-term stability.

Secondary hemostasis:

• It involves activation of clotting factors through enzymatic reactions. These reactions produce fibrin, which stabilizes the platelet plug.
• The resulting clot provides durable control of bleeding.
• After vessel repair, the clot is removed by fibrinolysis, restoring normal blood flow.
• Vascular injury triggers a sequence of tightly regulated events leading to clot formation.
• Failure of any component may result in excessive bleeding or abnormal clotting.
• Hemostasis is essential for maintaining circulatory integrity and preventing blood loss.

Steps of Hemostasis

• Hemostasis proceeds through three coordinated steps: vasoconstriction, platelet plug formation, and coagulation.

Vasoconstriction

• It is the immediate response to vascular injury.
• Vascular smooth muscle contracts, reducing blood flow at the injured site. This response initially occurs due to mechanical stimulation of the vessel wall.
• Activated platelets release serotonin and other vasoconstrictors that sustain this effect.
• Vasoconstriction limits blood loss and facilitates subsequent hemostatic events.

Temporary Hemostatic Plug Formation

• Platelets adhere to exposed subendothelial surfaces at the site of injury. This process is called adhesion and involves increased platelet surface reactivity.
• Platelets then bind to each other, forming aggregates at the injury site. This step is known as aggregation and strengthens the developing plug.
• Activated platelets release mediators such as adenosine diphosphate and thromboxane. These substances enhance vasoconstriction and recruit additional platelets.
• The resulting platelet plug temporarily seals the damaged vessel. This stage is termed primary or temporary hemostasis because the plug is unstable.

Blood Coagulation

• Blood coagulation is activated immediately after vascular injury. It leads to formation of a stable fibrin clot at the site of damage.
• Coagulation occurs around the platelet plug, converting it into a definitive hemostatic plug. This stage is termed secondary hemostasis because it follows platelet-mediated primary hemostasis.
• Vessel injury exposes collagen and releases tissue factors, initiating the clotting cascade.
• Sequential activation of clotting factors results in fibrin formation.
• The fibrin network stabilizes the clot and effectively prevents further blood loss.

Thrombopoiesis

• Thrombopoiesis is the process of platelet formation in bone marrow.
• Platelets are small, anucleate fragments derived from megakaryocytes.
• Development begins from hematopoietic stem cells through committed progenitor cells.

Stages of Development

• Megakaryoblasts are formed from precursor stem cells. These cells undergo megakaryopoiesis, producing mature megakaryocytes through intermediate stages.
• Cytoplasmic fragmentation of megakaryocytes releases platelets into circulation. This process ensures continuous platelet production for maintaining normal hemostasis.

Stem Cells

• Stem cells of myeloid lineage differentiate into colony-forming units for megakaryocytes.
• These progenitors give rise to megakaryoblasts, initiating platelet formation.

Megakaryoblasts

• Megakaryoblasts are large bone marrow cells, typically exceeding 15 micrometers.
• They possess basophilic cytoplasm and a multilobed nucleus, marking early thrombopoietic development.

Megakaryocytes

• Megakaryocytes are large bone marrow cells responsible for platelet formation.
• They develop through three stages: promegakaryocyte, granular megakaryocyte, and mature megakaryocyte.

Promegakaryocytes

• These cells are larger than megakaryoblasts, usually exceeding 20 micrometers.
• The cytoplasm is basophilic with a few granules near the centrosome.
• The nucleus appears curved or horse-shoe shaped.

Granular Megakaryocytes

• These cells are very large, measuring about 25 to 50 micrometers.
• The cytoplasm becomes acidophilic and contains numerous granules.
• The nucleus remains irregular or lobulated.

Mature Megakaryocytes

• These are the largest cells in bone marrow and are polyploid, indicating increased DNA content.
• The cytoplasm is abundant and rich in different granules, including alpha and dense granules.
• These granules contribute to the functional properties of platelets.
• Platelets are formed by cytoplasmic fragmentation of these cells.
• The size, number, and ploidy of megakaryocytes increase when platelet demand rises.
• The nucleus becomes more compact as the cell matures.
• These stages ensure efficient production of platelets for maintaining normal hemostasis.

Platelets

• Platelets are formed by fragmentation of megakaryocyte cytoplasm in bone marrow.
• Each megakaryocyte produces about 1,000 to 3,000 platelets.
• Daily platelet production is approximately 35,000 to 45,000 per microliter of blood, maintaining adequate levels for hemostasis.

Regulation of Thrombopoiesis

• Thrombopoiesis is regulated by feedback mechanisms that maintain stable platelet levels.
• Decreased platelet count stimulates production, while transfusion suppresses it.

Thrombopoietin

• It is the principal regulator produced mainly by the liver and partly by the kidney.
• It promotes megakaryocyte proliferation and maturation.
• Recombinant forms are used clinically in thrombocytopenia and have a half-life of 20 to 40 hours.

Interleukins

• Interleukin-1, interleukin-3, interleukin-6, and interleukin-11 enhance platelet production.
• They act directly on precursor cells without increasing thrombopoietin secretion.

GM-CSF

• It is produced by immune and stromal cells.
• It supports hematopoiesis, including platelet formation.
• These regulators ensure adequate platelet supply for normal hemostasis.

Life History

• Platelets have a half-life of about 4 days and circulate for 8 to 12 days.
• Aged platelets are removed by the reticuloendothelial system, mainly in the spleen.
• Platelet count increases after splenectomy and decreases in splenomegaly due to enhanced sequestration and destruction.

Structure And Functions

Structure

• Platelets are small, anucleate cell fragments specialized for hemostasis.
• Their membrane properties enable adhesion to injured vessels and aggregation with other platelets.
• They possess a well-developed cytoskeleton that supports shape change and movement.
• A specialized canalicular system facilitates transport and secretion of substances.
• Platelets contain membrane systems that regulate activation and release reactions.
• Upon activation, they form filopodia, increasing surface area for interaction.
• Numerous granules store mediators essential for clot formation and vascular repair.

Dimensions

• Platelets are small, spherical or oval bodies with a diameter of about 1.5 to 3.0 micrometers.
• Their size is roughly one-third to one-fourth that of red blood cells.
• Considerable variation in platelet size exists, with some larger forms exceeding 4 micrometers.

Cell Membrane

• The platelet surface is covered by a glycocalyx containing glycoproteins, glycolipids, and mucopolysaccharides.
• Presence of sialic acid imparts a negative charge, preventing spontaneous aggregation.
• The membrane is a phospholipid bilayer embedded with cholesterol and proteins.
• In resting state, glycoproteins prevent adhesion to intact endothelium.
• During activation, specific receptors facilitate adhesion and aggregation.
• Platelet membranes contain receptors for collagen, adenosine diphosphate, fibrinogen, and von Willebrand factor.

Membrane Glycoproteins

• Gp Ib-IX-V complex mediates adhesion to subendothelial collagen via von Willebrand factor.
• Gp IIb/IIIa complex binds fibrinogen and enables platelet aggregation after activation.
• Gp Ia-IIa acts as a collagen receptor, supporting adhesion independent of von Willebrand factor.
• These structural features allow platelets to rapidly respond to vascular injury and maintain effective hemostasis.

Cytoskeletal Systems

• The cytoskeletal system of platelets is divided into membrane-associated and cytoplasmic components.

Membrane Cytoskeleton

• It consists of spectrin networks linked to submembrane actin filaments.
• Filamin connects membrane glycoproteins with actin, providing structural stability.
• Additional proteins such as talin, vinculin, and vimentin strengthen membrane organization.
• This system maintains the discoid shape of resting platelets.
• It also facilitates platelet spreading after adhesion to damaged endothelium.

Cytoplasmic Cytoskeleton

• The cytoplasm contains a contractile network of microfilaments and microtubules.
• These structures enable shape change during platelet activation.

Microtubules

• Submembrane microtubules form a circumferential band supporting platelet shape.
• They are composed of alpha and beta tubulin proteins.
• Motor proteins such as dynein and kinesin assist intracellular transport.
• Microtubules provide mechanical support and contribute to platelet contraction.
• Overall, the cytoskeletal system enables rapid structural changes required for adhesion, aggregation, and secretion during hemostasis.

Microfilaments

• Microfilaments in platelets are mainly composed of actin, with associated myosin filaments.
• They form the contractile system responsible for platelet shape change.
• In resting platelets, microfilaments are less prominent.
• Upon activation, actin polymerizes into bundles, increasing structural organization.
• This system enables formation of projections and supports granule secretion through canalicular channels during hemostasis.

Cellular Systems

• Platelets possess specialized cellular systems that support secretion and activation during hemostasis.
• The two main systems are the open canalicular system and the dense tubular system.

Open Canalicular System

• It consists of membrane invaginations that extend deep into the cytoplasm.
• These channels communicate with the platelet surface.
• They serve as pathways for rapid release of granule contents.
• Granules can fuse with canalicular membranes, allowing efficient secretion.
• This system enhances the speed and extent of platelet activation.

Dense Tubular System

• It is derived from residual endoplasmic reticulum and forms a closed network.
• It lies close to the canalicular system within the cytoplasm.
• It stores ionized calcium, which is essential for platelet activation.
• Proteins such as calreticulin help in calcium binding and storage.
• Release of calcium initiates and amplifies platelet secretion and aggregation.

Cytoplasmic Organelles

• Platelets contain mitochondria that provide energy for cellular processes.
• Microtubules and microfilaments support shape change and contraction.
• Occasional Golgi elements may be present, but are limited.

Platelet Granules

• Platelets contain numerous granules that release mediators during activation.
• Alpha granules are abundant and contain proteins involved in coagulation and repair.
• Each platelet contains approximately 50 to 80 alpha granules of about 200 nanometers diameter.
• Dense granules are fewer, about 3 to 8 per platelet, and are smaller in size.
• They contain substances such as adenosine diphosphate, serotonin, calcium, and adenosine triphosphate.
• Release of granule contents promotes adhesion, aggregation, and vasoconstriction, ensuring effective hemostasis.

Properties of Platelets

• Platelets exhibit three key properties: adhesion, aggregation, and activation with release.

Adhesion

• Platelets adhere to exposed subendothelial collagen at sites of vascular injury.
• This process is mediated by von Willebrand factor, which links platelets to collagen.
• Platelet surface receptor glycoprotein Ib plays an essential role in this interaction.
• Adhesion occurs only at damaged sites and not on intact endothelium.
• This initial step is critical for formation of the primary hemostatic plug.

Table 20.1: Contents of platelet granules.

Granule Type	Key Components	Physiological Role
Alpha granules	von Willebrand factor, fibrinogen, platelet factor 4, growth factors, coagulation factors	Promote adhesion, coagulation, tissue repair, and regulation of fibrinolysis
Dense granules	Serotonin, adenosine diphosphate, adenosine triphosphate, calcium, pyrophosphate	Enhance platelet activation, aggregation, and vasoconstriction during hemostasis

Aggregation

• Platelet aggregation is the process by which platelets adhere to each other at the injury site.
• It is mediated by fibrinogen bridging between Gp IIb/IIIa receptors on adjacent platelets.
• Mediators such as adenosine diphosphate, thrombin, and platelet activating factor enhance aggregation.

Activation and Release (Secretion)

• Platelet activation occurs when platelets bind to collagen or interact with other platelets.
• It is enhanced by mediators such as thrombin and adenosine diphosphate.
• Activated platelets undergo shape change, becoming spherical with pseudopodia.
• This change results from cytoskeletal reorganization involving microtubules and actin–myosin contraction.
• Platelets then release granule contents through the open canalicular system.
• This process is called the release reaction or secretion.
• Released substances amplify platelet activation, aggregation, and vasoconstriction, strengthening hemostasis.

Functions of Platelets

1. Platelets play a central role in maintaining vascular integrity and preventing blood loss.
2. In primary hemostasis, they form a temporary plug at sites of vascular injury.
3. They release serotonin, which promotes vasoconstriction and reduces bleeding.
4. Platelets support blood coagulation by providing a phospholipid surface and releasing factors such as platelet factor 4 and clotting factors.
5. They contribute to clot retraction, which stabilizes and strengthens the formed clot.
6. Platelets help regulate fibrinolysis, ensuring controlled breakdown of clots.
7. They can engulf small particles, including immune complexes, showing limited phagocytic activity.
8. Platelets store and transport various bioactive substances important for hemostasis.
9. They release platelet-derived growth factor, which promotes repair and regeneration of vascular endothelium.
10. These functions collectively support effective hemostasis and vascular healing.

Table 20.2: Variations in platelet count.

Platelet Count Change	Common Causes
Thrombocytosis (increased count)	Myeloproliferative disorders, iron deficiency, acute blood loss, post-splenectomy state, malignancies, chronic infections, surgery, and certain drugs
Thrombocytopenia (decreased count)	Bone marrow failure, hypersplenism, immune destruction, infections such as human immunodeficiency virus, drugs, chemotherapy, irradiation, and hereditary disorders

Normal Count and Variations

• The normal platelet count ranges from 150,000 to 400,000 per cubic millimeter of blood.

Thrombocytopenia

• It is defined as platelet count below 150,000 per cubic millimeter.
• Significant bleeding risk occurs when count falls below 50,000 per cubic millimeter.
• Causes include immune disorders, bone marrow failure, hypersplenism, leukemia, chemotherapy, and radiation.
• Approximately 70 percent of platelets circulate, while 30 percent are stored in the spleen.
• Splenectomy increases platelet count, whereas hypersplenism reduces it.

Thrombocytosis

• It refers to elevated platelet count above normal range.
• It occurs in myeloproliferative disorders, iron deficiency, infections, surgery, and after acute blood loss.

Role Of Platelet In Hemostasis

• Platelets play a crucial role in arresting bleeding and maintaining vascular integrity.
• Hemostasis occurs in two stages: temporary and definitive phases.
• After vascular injury, platelets adhere and aggregate to form a platelet plug.
• This plug provides rapid but temporary control of bleeding.
• Simultaneously, coagulation pathways generate fibrin to stabilize the plug.
• Platelets also support blood coagulation, promote clot retraction, and regulate fibrinolysis.
• These coordinated actions ensure effective and sustained hemostasis.

Role in Temporary Hemostasis

• Temporary hemostasis occurs immediately after vascular injury through formation of a platelet plug.
• Platelets adhere to the damaged surface, aggregate, and undergo release reaction.
• The resulting platelet thrombus provides rapid control of bleeding but remains unstable without fibrin support.

Platelet Adhesion

• Platelet adhesion is the attachment of platelets to the exposed subendothelial surface after vascular injury.
• Damage to endothelium exposes collagen and von Willebrand factor, which attract platelets.
• Platelet surface receptors bind to these components, initiating adhesion.
• The degree of injury influences adhesion; deeper injury releases more activating factors and increases platelet response.
• The site of injury also affects adhesion; mucocutaneous vessels depend more on platelet activity than deeper tissues.
• Age alters vascular structure, and platelet adhesion may decrease in elderly individuals.
• Hematocrit influences platelet distribution; higher red cell concentration pushes platelets toward the vessel wall, enhancing adhesion.
• In anemia, reduced red cell mass decreases platelet interaction with the endothelium.
• Blood flow velocity plays an important role; slower flow favors adhesion by allowing more contact time.
• Rapid flow reduces platelet attachment due to increased shear forces.
• Vessel size affects the number of circulating platelets reaching the injury site.
• Smaller vessels facilitate closer interaction between platelets and vessel walls.
• These factors collectively regulate the efficiency of platelet adhesion, which is essential for initiation of primary hemostasis.

Platelet Aggregation

• Platelet aggregation follows adhesion and leads to accumulation of platelets at the injury site.
• It is mediated by fibrinogen bridging between Gp IIb/IIIa receptors on adjacent platelets.
• Thrombin enhances aggregation and platelet activation.
• Activated platelets release mediators such as adenosine diphosphate and platelet activating factor.
• These substances amplify recruitment of additional platelets.
• Aggregation results in formation of a platelet mass that contributes to the temporary hemostatic plug.

Platelet Activation and Release

• Platelet activation begins after adhesion to damaged endothelium or exposure to tissue factors.
• Mediators such as thrombin, adenosine diphosphate, and platelet activating factor enhance activation.
• Actin polymerization leads to formation of pseudopodia, increasing surface area.
• Activated platelets undergo structural changes and become more reactive.
• They release granule contents through the open canalicular system.
• This release reaction amplifies platelet aggregation and promotes effective hemostasis.

Table 20.3: Factors that influence platelet adhesion, aggregation and activation.

Effect on Platelets	Key Factors
Promote adhesion and activation	Adenosine diphosphate, thrombin, platelet activating factor, serotonin, fibrinogen, von Willebrand factor, endothelial injury, reduced blood flow
Inhibit activation	Rapid blood flow, prostacyclin, nitric oxide, and inhibitors of thrombin formation and activity

Through Platelet Activating Factor

• Platelet activating factor enhances platelet activation after adhesion to injured vessels.
• It is released from neutrophils, monocytes, and platelets.
• It acts through G protein signaling, activating phospholipase C and forming diacylglycerol.
• This increases intracellular calcium by releasing it from dense tubular systems.
• Elevated calcium triggers contraction of microfilaments.
• Granules move toward the open canalicular system and fuse with its membrane.
• Their contents are released by exocytosis to the exterior.
• Platelets undergo shape change and increased motility during this process.

Through Thromboxane and Serotonin

• Diacylglycerol activates phospholipase A2, generating arachidonic acid from membrane phospholipids.
• Arachidonic acid is converted to thromboxane A2 via cyclooxygenase.
• Thromboxane A2 promotes vasoconstriction and platelet aggregation.
• Serotonin released from platelets further enhances vasoconstriction and supports hemostasis.

Through Thrombospondin and Thrombonectin

• Thrombospondin and thrombonectin released from platelet granules enhance the contractile activity of platelets.
• They promote exocytosis and facilitate release of granule contents.
• Platelet function is normally regulated by a balance between activating and inhibitory factors.
• Disturbance of this balance can lead to intravascular thrombosis and tissue infarction.

Other Hemostatic Functions

Role in Blood Coagulation

• Platelets enhance blood coagulation by increasing procoagulant activity after activation.
• Platelet factor 4 acts as a cofactor in clotting reactions.
• Platelets synthesize clotting factors V and XI.
• Surface phospholipids accelerate activation of key coagulation factors.
• These actions promote conversion of prothrombin to thrombin.
• Overall, platelets significantly accelerate thrombin formation and stabilize clot development.

Role in Clot Retraction

• Clot retraction occurs when platelets within a fibrin clot contract and reduce its size.
• Platelet filopodia attach to fibrin strands and pull them inward.
• Contraction of the platelet cytoskeleton leads to compaction of the clot and expulsion of serum.
• In vivo, this process strengthens the thrombus and promotes wound healing.
• Clot retraction also reduces susceptibility of the clot to early breakdown.
• Platelet deficiency results in prolonged or impaired clot retraction.

Role in Thrombolysis

• Platelets release both profibrinolytic and antifibrinolytic factors.
• Substances such as tissue plasminogen activator and plasmin promote clot breakdown.
• Platelets also secrete inhibitors like plasminogen activator inhibitor and alpha-2 antiplasmin.
• The antifibrinolytic effect generally predominates in vivo.
• Platelet-rich clots are therefore more resistant to fibrinolysis.
• Clot retraction further stabilizes the thrombus and limits thrombolytic activity.

Role of Vascular Wall in Hemostasis

• The vascular endothelium regulates hemostasis by producing both inhibitory and promotive factors.

Inhibitors of Hemostasis

• Thrombomodulin binds thrombin and activates protein C, which inactivates factors V and VIII.
• Protein S acts as a cofactor for protein C and enhances anticoagulant activity.
• Heparin-like molecules increase antithrombin activity and inhibit clotting factors.
• Prostacyclin causes vasodilation and prevents platelet aggregation.
• Tissue plasminogen activator converts plasminogen to plasmin and promotes fibrinolysis.

Promoters of Hemostasis

• Tissue factor initiates the extrinsic coagulation pathway after injury.
• Von Willebrand factor mediates platelet adhesion to exposed subendothelium.
• Platelet activating factor enhances platelet aggregation and activation.
• Vasoconstriction of injured vessels reduces blood flow and limits bleeding.
• Exposed subendothelial collagen promotes platelet adhesion and activates clotting pathways.
• A balance between these opposing actions ensures controlled hemostasis and prevents either excessive bleeding or thrombosis.

Platelet Function Tests

• Platelet function tests assess number and functional integrity of platelets in hemostasis.
• Platelet count measures circulating platelets.
• Normal range is 150,000 to 400,000 per cubic millimeter.
• Bleeding time is significantly prolonged when count falls below 50,000 per cubic millimeter.
• It is essential for evaluating suspected bleeding disorders.
• Bleeding time evaluates platelet function and vascular integrity.
• It is commonly assessed before surgical or dental procedures.
• It is prolonged in thrombocytopenia and in functional platelet defects.
• Platelet aggregation tests assess the ability of platelets to clump together.
• Aggregating agents are added, and changes in light transmission are measured.
• Reduced aggregation indicates functional abnormalities.
• Platelet adhesiveness test measures the ability of platelets to adhere to surfaces.
• Blood is passed through a column, and platelet retention is calculated.
• Reduced adhesiveness suggests defective platelet function.
• Clot retraction time reflects platelet contractile function.
• About 50 percent retraction occurs within one hour under normal conditions.
• Reduced retraction indicates platelet deficiency or dysfunction.
• These tests together help diagnose disorders affecting primary hemostasis.

Common Platelet Dysfunctions

• Platelet dysfunctions commonly result from reduced platelet count or immune-mediated destruction, leading to impaired hemostasis.

Idiopathic Thrombocytopenic Purpura

• Idiopathic thrombocytopenic purpura is an autoimmune disorder characterized by low platelet count.
• Antiplatelet antibodies bind to platelet membrane glycoproteins, causing splenic destruction.
• It occurs as childhood and adult forms.
• Childhood form is usually mild and resolves within about six months.
• Adult form is more persistent and more common in females.
• Patients present with spontaneous bleeding, including petechiae, ecchymoses, epistaxis, and gum bleeding.
• Laboratory findings show thrombocytopenia, possible anemia, and increased bone marrow megakaryocytes.
• Management includes corticosteroids and, in resistant cases, splenectomy.

Thrombocytopenia in Pregnancy

• Thrombocytopenia during pregnancy is often mild and asymptomatic.
• Gestational thrombocytopenia typically occurs in late pregnancy and resolves after delivery.
• Platelet count may fall below 70,000 per cubic millimeter in the third trimester.
• It may increase bleeding risk during delivery.
• It can also be associated with hypertensive disorders such as preeclampsia.
• Severe reduction below 50,000 per cubic millimeter indicates higher clinical concern.

Neonatal Autoimmune Thrombocytopenia

• Neonatal autoimmune thrombocytopenia occurs due to maternal antibodies against fetal platelet antigens.
• Platelet count is often below 50,000 per cubic millimeter.
• It may be associated with hemolytic conditions.
• The condition is more severe when the mother has autoimmune platelet disorders.
• Treatment includes platelet transfusion, corticosteroids, and immunoglobulin therapy.
• Early recognition of these conditions is essential to prevent serious bleeding complications.